Citations 3
572 | PATIENT‐REPORTED OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA PATIENTS TREATED WITH EPCORITAMAB: OVERALL AND SUBGROUP ANALYSIS BY BASELINE SYMPTOM BURDEN
Johnson, P. C., Nsiah, Irene , Ding, Zhijie , Mutebi, Alex , Patah, Poliana, Favaro, Enrico, Dueck, Amylou C. , Ghione, Paola , Major, Ajay , Wang, Anthony , Alshreef, Abualbishr , Yu, Jovian , Favaro, E., Jurczak, Wojciech
Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available
Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma
Yeh, Su‐Peng , Gkasiamis, Argyrios, Patah, Poliana, Patel, Arpankumar , Nowakowski, Grzegorz S. , Westin, Jason R. , Martı́n, Alejandro , Hoffmann, Marc Steven , Vassilakopoulos, Theodoros P. , Li, Ju
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9475-9477
THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
Nowakowski, G. S., Kesanakurthy, V., Gkasiamis, Argyrios, Patah, Poliana, Delarue, Richard, Wang, T., Xian, Dehai , Martin, Peter , Morschhauser, Franck , Cartron, Guillaume , Li, J., Xian, D., Fox, Christopher P.
Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available